BofA Securities Upgrades GlaxoSmithKline (GSK:LN) (GSK) to Neutral
Tweet Send to a Friend
BofA Securities analyst Sachin Jain upgraded GlaxoSmithKline (GSK:LN) (NYSE: GSK) from Underperform to Neutral with a price target of INR20.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
